Opicapone for the treatment of Parkinson’s disease: an update

References

• Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–1649.
   PubMed Web of Science ®Google Scholar
• Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124:901–905.
   PubMed Web of Science ®Google Scholar
• Szatmári S Jr, Ajtay A, Bálint M, et al. Linking individual patient data to estimate incidence and prevalence of Parkinson’s disease by comparing reports of neurological services and pharmacy prescription refills at a nationwide level. Front Neurol. 2019;10:640.
   PubMed Web of Science ®Google Scholar
• Dickson DW. Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012;2:1–15.
   Web of Science ®Google Scholar
• Rogers G, Davies D, Pink J, et al. Parkinson’s disease: summary of updated NICE guidance. BMJ. 2017;358:j1951.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Ferreira JJ, Lees A, et al. Opicapone for the treatment of Parkinson’s disease: A review of a new licensed medicine. Mov Disord. 2018;33:1528–1539.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28:1064–1071.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Schapira AH. Therapeutic prospects for Parkinson disease. Ann Neurol. 2013;74:337–347.
   PubMed Web of Science ®Google Scholar
• Annus Á, Vécsei L. Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy. Drug Des Devel Ther. 2017;11:143–151.
   PubMed Web of Science ®Google Scholar
• Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson’s disease. Curr Clin Pharmacol. 2007;2:234–243.
   PubMedGoogle Scholar
• Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75:157–174.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Opicapone: a review in Parkinson’s disease. Drugs. 2016;76:1293–1300.
   PubMed Web of Science ®Google Scholar
• Rodrigues FB, Ferreira JJ. Opicapone for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2017;18:445–453.
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154–165.
   PubMed Web of Science ®Google Scholar
• Palma N, Bonifacio MJ, Loureiro AI, et al. Computation of binding affinity of catechol-O-methyltransferase-opicapone complexes. Parkinsonism Relat Disord. 2012;18:S125.
   PubMedGoogle Scholar
• Kiss LE, Ferreira HS, Torrão L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010;53:3396–3411.
   PubMed Web of Science ®Google Scholar
• Almeida L, Rocha JF, Falcão A, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet. 2013;52:139–151.
   PubMed Web of Science ®Google Scholar
• Rocha JF, Falcão A, Santos A, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014;70:1059–1071.
   PubMed Web of Science ®Google Scholar
• Rocha JF, Almeida L, Falcão A, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76:763–775.
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Rocha JF, Falcão A, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol. 2015;22:815–825.
   PubMed Web of Science ®Google Scholar
• Falcão A, Santos A, Ferreira J, et al. Decision-making process for opicapone’s bedtime regimen [abstract]. Mov Disord. 2017;32 (suppl 2).
   Google Scholar
• Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther. 1995;57:508–517.
   PubMed Web of Science ®Google Scholar
• Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol. 1994;46:151–157.
   PubMed Web of Science ®Google Scholar
• Lopes N, Ferreira J, Lees A, et al. Efficacy of opicapone in combination with dopamine agonists or MAO-B inhibitors on the treatment of motor fluctuations in Parkinson’s disease. Eur J Neurol. 2015;22:439.
   Web of Science ®Google Scholar
• Lopes N, Ferreira J, Lees A, et al. Exploratory efficacy of opicapone in combination with dopamine agonists or MAO-B inhibitors on the treatment of motor fluctuations in Parkinson’s disease. Mov Disord. 2015;30:S101.
   Web of Science ®Google Scholar
• Rocha JF, Santos A, Falcão A, et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol. 2014;70:279–286.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Ongentys assessment report; 28 April 2016. EMA/343011/2016.
   Google Scholar
• Santos A, Falcao A, Rocha J, et al. Influence of food on opicapone pharmacokinetics and pharmacodynamics. Eur J Neurol. 2017;24:S123–444.
   Web of Science ®Google Scholar
• Falcão A, Rocha JF, Santos A, et al. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects. Clin Pharmacol Drug Dev. 2016;5:150–161.
   PubMed Web of Science ®Google Scholar
• Rocha JF, Sicard É, Fauchoux N, et al. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics. Br J Clin Pharmacol. 2017;83:540–553.
   PubMed Web of Science ®Google Scholar
• Svetel M, Tomić A, Kresojević N, et al. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2018;14:353–360.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Rosa MM, Ferreira JJ. Clinical pharmacology review of opicapone for the treatment of Parkinson’s disease. Neurodegener Dis Manag. 2016;6:349–362.
   PubMed Web of Science ®Google Scholar
• Rocha JF, Ferreira JJ, Falcão A, et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, Catechol-O-methyltransferase activity and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev. 2016;5:232–340.
   PubMed Web of Science ®Google Scholar
• Ferreira J, Lees A, Rascol O, et al. Switching entacapone or placebo to opicapone open-label: efficacy results of the BIPARK-I 1-year extension study. J Neurol Sci. 2017;381:561–756.
   Web of Science ®Google Scholar
• Ferreira JJ, Lees A, Rocha JF, et al. Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol. 2019;26:953–960.
   PubMed Web of Science ®Google Scholar
• Lopes N, Ferreira J, Lees A, et al. Efficacy of opicapone in Parkinson’s disease patients with motor fluctuations at different stages of symptom progression. Presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders, Vancouver; 2017 June 4–8; British Columbia, Canada. Meeting Abstract; 2017.
   Google Scholar
• Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:197–206.
   PubMed Web of Science ®Google Scholar
• Lees AJ, Ferreira JJ, Reichmann H, et al. Onset and stabilization of opicapone treatment effects in fluctuating Parkinson’s disease patients: exploratory by-week efficacy analysis of pooled phase III studies [abstract]. Mov Disord. 2016;31(suppl):2).
   Google Scholar
• Pinto R, l’Hostis P, Patat A, et al. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. Clin Pharmacol Drug Dev. 2015;4:454–462.
   PubMed Web of Science ®Google Scholar
• Pinto R, Vaz-da-Silva M, Lopes N, et al. Cardiac safety of opicapone in patients with Parkinson’s disease: analysis of the centralized phase III ECG dataset. Mov Disord. 2015;30:S112.
   Google Scholar
• Caldas CA, Teodoro T, Ferreira JJ. The launch of opicapone for Parkinson’s disease: negatives versus positives. Expert Opin Drug Saf. 2018;17:331–337.
   PubMed Web of Science ®Google Scholar